That is a really important point. Not only do we contribute more to the global vaccination funding programme than any other country—and we hosted the GAVI summit, which raised over £8 billion for global vaccine research—but we are engaged with other countries on the two British vaccine candidates, particularly the Oxford one, because it is so much further advanced. It is the most advanced in the world and the soonest hope for a vaccine, should it come off—touch wood; none of these things is certain. We secured early doses here in the UK, and it was confirmed yesterday that these are being manufactured, with the contract agreed between AstraZeneca and the manufacturer. AstraZeneca is now engaging with countries across the world—in Europe, in the United States where a deal has already been signed, and elsewhere—to ensure that, if the vaccine works, it will be available globally.